skip to Main Content

Cover of November 2020 TAGline: 'The Struggle of a Lifetime' (Continued)
Image montage of TAG Limited Art Editions
Image link to About the COVID-19 Project page
Research in Action Awards 2020 - watch the video now!

Pipeline Reports

The current ones are all online and available for download now.




November 19, 2020
TAG Applauds Dr. Demetre Daskalakis’ Appointment as CDC Director of the Division of HIV/AIDS Prevention: NYC’s Loss is America’s Gain
Statement / Press
Treatment Action Group applauds the appointment of Dr. Demetre Daskalakis to helm the U.S. Centers for Disease Control and Prevention (CDC)’s Division of HIV/AIDS Prevention (DHAP). We can think of no better public health practitioner to embody true innovation and disrupt the status quo in our national HIV prevention response.

November 16, 2020
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

November 16, 2020
Efficacy News from Second COVID-19 Vaccine Trial Underscores Need for Transparency and Cooperation Between Outgoing and Incoming US Administrations
Statement / Press
AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19.

November 12, 2020
COVID-19 and Impacted Communities: a Media Communications Guide
This easy-to-use guide is designed to provide journalists and communication professionals the tools needed to ensure accurate reporting and curb any related stigma associated with the novel coronavirus SARS-COV-2, also known and reported as COVID-19. We invite you to use this to inform your own writing and to share it…

November 12, 2020
Treatment Action Group Statement on Early Findings from HPTN 084
Statement / Press
Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.

Back To Top